Top

International Urogynecology Journal

Published in:

01-04-2015 | Original Article

Impact of anticholinergic load on bladder function

Authors: Jacquia F. De La Cruz, Cassandra Kisby, Jennifer M. Wu, Elizabeth J. Geller

Published in: International Urogynecology Journal | Issue 4/2015

Abstract

Introduction and hypothesis

Our aim was to evaluate the impact of anticholinergic load on urinary retention based on postvoid residual (PVR) on micturition study. Secondary objectives were to assess the effect of anticholinergic load on other urodynamic parameters.

Methods

This was a retrospective cohort study of women who underwent urodynamics (UDS) at one academic institution. All medications being taken by the women at the time of UDS were scored using the anticholinergic risk scale (ARS). This validated scale assigns rank scores to each medication based on its anticholinergic potential. Women were dichotomized into two anticholinergic cohorts: low (0–1) or high (≥2) ARS scores.

Results

During the study period, 599 women underwent UDS. ARS scores ranged from 0 to 8, with 440 (73.5 %) having low (≤1) and 159 (26.5 %) having high (≥2) scores. For our primary outcome of micturition PVR, there was no difference between low and high ARS groups (66.8 ± 108.6 ml vs. 78.6 ± 121.0 ml, p = 0.25). There was also no difference between ARS groups in other voiding function parameters. Sensitivity analyses did demonstrate a difference in micturition PVR, with ARS 0–4 (n = 583) vs. ARS ≥ 5 (n = 16): 68.3 ± 109.1 ml vs. 127.5 ± 185.7 (p < 0.01) ,as well as maximum cystometric capacity (MCC): 420.8 ± 181.3 ml vs. 526.1 ± 252.4 ml (p = 0.02).

Conclusions

Despite the prevalence and risks associated with the use of medications with anticholinergic properties, a cumulative effect on bladder function was only demonstrated with very high anticholinergic risk scores of ≥5.

Geller EJ, Crane AK, Wells EC et al (2012) Effect of anticholinergic use for the treatment of overactive bladder on cognitive function in postmenopausal women. Clin Drug Investig 32(10):697–705CrossRefPubMedCentralPubMed

Milsom I, Kaplan SA, Coyne KS et al (2012) Effect of bothersome overactive bladder symptoms on health-related quality of life, anxiety, depression, and treatment seeking in the United States: results from EpiLUTS. Urology 80(1):90–96CrossRefPubMed

Kay GG, Abou-Donia MB, Messer WS Jr et al (2005) Antimuscarinic drugs for overactive bladder and their potential effects on cognitive function in older patients. J Am Geriatr Soc 53(12):2195–2201CrossRefPubMed

Abrams P, Andersson KE, Buccafusco JJ et al (2006) Muscarinic receptors: their distribution and function in body systems, and the implications for treating overactive bladder. Br J Pharmacol 148(5):565–578CrossRefPubMedCentralPubMed

Boustani M (2008) ea. Impact of anticholinergics on the aging brain: a review and practical application. Aging Health 4(3):311–320CrossRef

Carnahan RM, Lund BC, Perry PJ et al (2006) The Anticholinergic Drug Scale as a measure of drug-related anticholinergic burden: associations with serum anticholinergic activity. J Clin Pharmacol 46(12):1481–1486CrossRefPubMed

Natalin R, Lorenzetti F, Dambros M (2013) Management of OAB in those over age 65. Curr Urol Rep 14(5):379–385CrossRefPubMed

Rudolph JL, Salow MJ, Angelini MC et al (2008) The anticholinergic risk scale and anticholinergic adverse effects in older persons. Arch Intern Med 168(5):508–513CrossRefPubMed

Duran CE, Azermai M, Vander Stichele RH (2013) Systematic review of anticholinergic risk scales in older adults. Eur J Clin Pharmacol 69(7):1485–1496CrossRefPubMed

10.

Hanlon JT, Schmader KE, Ruby CM et al (2001) Suboptimal prescribing in older inpatients and outpatients. J Am Geriatr Soc 49(2):200–209CrossRefPubMed

11.

Scheife R, Takeda M (2005) Central nervous system safety of anticholinergic drugs for the treatment of overactive bladder in the elderly. Clin Ther 27(2):144–153CrossRefPubMed

12.

Verhamme KM, Sturkenboom MC, Stricker BH, Bosch R (2008) Drug-induced urinary retention: incidence, management and prevention. Drug Saf : Int J Med Toxicol Drug Experience 31(5):373–388CrossRef

13.

Walter PJ, Dieter A, Siddiqui NY et al (2014) Perioperative anticholinergic medications and risk of catheterization after urogynecologic procedures. Female Pelvic Med Reconstr Surg 20(3):163–167CrossRefPubMed

14.

Haylen BT, de Ridder D, Freeman RM et al (2010) An International Urogynecological Association (IUGA)/International Continence Society (ICS) joint report on the terminology for female pelvic floor dysfunction. Int Urogynecol J 21(1):5–26CrossRefPubMed

15.

Jonas U, Hofner K, Madersbacher H et al (1997) Efficacy and safety of two doses of tolterodine versus placebo in patients with detrusor overactivity and symptoms of frequency, urge incontinence, and urgency: urodynamic evaluation. Int Study Group World J Urol 15(2):144–151CrossRef

16.

Carnahan RM, Lund BC, Perry PJ et al (2002) The relationship of an anticholinergic rating scale with serum anticholinergic activity in elderly nursing home residents. Psychopharmacol Bull 36(4):14–19PubMed

17.

Kersten H, Molden E, Willumsen T et al (2013) Higher anticholinergic drug scale (ADS) scores are associated with peripheral but not cognitive markers of cholinergic blockade. Cross sectional data from 21 Norwegian nursing homes. Br J Clin Pharmacol 75(3):842–849PubMedCentralPubMed

18.

Pasina L, Djade CD, Lucca U et al (2013) Association of anticholinergic burden with cognitive and functional status in a cohort of hospitalized elderly: comparison of the anticholinergic cognitive burden scale and anticholinergic risk scale: results from the REPOSI study. Drugs Aging 30(2):103–112CrossRefPubMed

19.

Tanaka Y, Masumori N, Tsukamoto T (2010) Urodynamic effects of solifenacin in untreated female patients with symptomatic overactive bladder. Int J Urol 17(9):796–800CrossRefPubMed

20.

Hsiao SM, Chang TC, Wu WY et al (2011) Comparisons of urodynamic effects, therapeutic efficacy and safety of solifenacin versus tolterodine for female overactive bladder syndrome. J Obstet Gynaecol Res 37(8):1084–1091CrossRefPubMed

21.

Wu WY, Hsiao SM, Chang TC et al (2011) Changes in urodynamic parameters after tolterodine treatment for female overactive bladder syndrome with or without voiding dysfunction. J Obstet Gynaecol Res 37(5):436–441CrossRefPubMed

22.

Wagg A, Malone-Lee J (2003) Pressure-flow variables in patients treated with tolterodine for detrusor overactivity. BJU Int 92(9):969–971CrossRefPubMed

Title: Impact of anticholinergic load on bladder function
Authors: Jacquia F. De La Cruz
Cassandra Kisby
Jennifer M. Wu
Elizabeth J. Geller
Publication date: 01-04-2015
Publisher: Springer London
Published in: International Urogynecology Journal / Issue 4/2015
Print ISSN: 0937-3462
Electronic ISSN: 1433-3023
DOI: https://doi.org/10.1007/s00192-014-2548-x

At a glance: The STEP trials

Springer Medicine

Impact of anticholinergic load on bladder function

Abstract

Introduction and hypothesis

Methods

Results

Conclusions

At a glance: The STEP trials

Springer Medicine

Abstract

Introduction and hypothesis

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 4/2015

Histopathology of excised midurethral sling mesh

Pharmacological treatment of pure stress urinary incontinence: a narrative review

Pelvic organ prolapse in the neonate: report of two cases and review of the literature

Small bowel surgery for the gynecologist specializing in benign disease

Quality of information on pelvic organ prolapse on the Internet

Can highly purified collagen coating modulate polypropylene mesh immune-inflammatory and fibroblastic reactions? Immunohistochemical analysis in a rat model